#tils Many people overlooking the significance of Sanofi IL6 results out today. A 4 fold improvement in patients treated with IL6 inhibitor tocilizumab administered orally. #TILS have an IL6 inhibitor in TZLS-501 and a patent about administering through a nebuliser.
Yes very nearly 4 fold improvement in IL6 patients TILS are in a great position now to get EUA FDA approval and fast track trials. I think they knew already the results would be this good hence to extra potential $20m raise
I dont really understand how they could've been ahead of the curve given it was only 6/7 weeks ago that Roche stated their IL6 drug could have implications in treating CVD19... Surely waiting for the results of the studies from Roche and Sanofi are better than kicking off expensive trials.. We await FDA news but if the results from Roche which are expected imminently are as good as what's being reported (77% improvement in Italy) then given we can administer through a nebuliser then I would expect that as a minimum.
Also please remember that unlike other diagnistic testing companies TZL-501 will work in future strains of Covid virus and we are in a royalty program with BRistol Myers Squib.
Then we've got all the other business units on top...
Gabrielle owns 47% of the company and has sold his previous companies for $bns
Fund % short change Date changed TT International Asset Management Ltd 1.26% 0.62% 25 Mar 2020 Lombard Odier Asset Management (Europe) Limited 0.60% 0.02% 18 Mar 2020 Ennismore Fund Management Limited 2.42% 0.12% 5 Mar 2020 Engadine Partners LLP 1.91% 0.29% 11 Mar 2020 AQR Capital Management, LLC 0.59% -0.01% 17 Jan 2020 Total 6.78%
March 17, 2020 | Published by Eddie Stobart The health, safety and wellbeing of our employees through these unprecedented times remains paramount.
Economic uncertainty has led to market disruption, but we have implemented pragmatic measures to support our preparedness and ongoing ability to deliver services to customers to the same consistently high standards.
Like other key members of the supply chain, we are all experiencing exceptional volumes that we would typically see around Christmas.
Due to effective planning, our business is well placed to continue supporting all our customers’ needs, fulfilling all work as usual, while also safeguarding the wellness of our employees.
We applaud the Government’s recent announcement for recognising the key role the logistics sector are providing in such turbulent times.